338 related articles for article (PubMed ID: 25308528)
21. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.
Zhou L; Li K; Shi YL; Hamzavi I; Gao TW; Henderson M; Huggins RH; Agbai O; Mahmoud B; Mi X; Lim HW; Mi QS
Pigment Cell Melanoma Res; 2012 Sep; 25(5):602-11. PubMed ID: 22591262
[TBL] [Abstract][Full Text] [Related]
22. Vitiligo: Pathogenesis, clinical variants and treatment approaches.
Iannella G; Greco A; Didona D; Didona B; Granata G; Manno A; Pasquariello B; Magliulo G
Autoimmun Rev; 2016 Apr; 15(4):335-43. PubMed ID: 26724277
[TBL] [Abstract][Full Text] [Related]
23. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of functional T-regs in vitiligo: our experience and mini-review of the literature.
Richetta A; D'Epiro S; Salvi M; Campoli M; Giancristoforo S; Mattozzi C; Macaluso L; Luci C; Cantisani C; Carboni V; Zanniello R; Zampetti M; Milana B; Morrone S; Calvieri S
Eur J Dermatol; 2013 Apr; 23(2):154-9. PubMed ID: 23608724
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA‑155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo.
Lv M; Li Z; Liu J; Lin F; Zhang Q; Li Z; Wang Y; Wang K; Xu Y
Mol Med Rep; 2019 Oct; 20(4):3617-3624. PubMed ID: 31485649
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis of FOXP3+ regulatory T cells in healthy human skin and autoimmune dermatoses.
Terras S; Gambichler T; Moritz RK; Altmeyer P; Lambert J
Int J Dermatol; 2014 Mar; 53(3):294-9. PubMed ID: 23968190
[TBL] [Abstract][Full Text] [Related]
27. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.
Kemp EH; Gavalas NG; Gawkrodger DJ; Weetman AP
Autoimmun Rev; 2007 Jan; 6(3):138-42. PubMed ID: 17289548
[TBL] [Abstract][Full Text] [Related]
28. CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.
Eby JM; Kang HK; Tully ST; Bindeman WE; Peiffer DS; Chatterjee S; Mehrotra S; Le Poole IC
J Invest Dermatol; 2015 Jun; 135(6):1574-1580. PubMed ID: 25634358
[TBL] [Abstract][Full Text] [Related]
29. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
30. Vitiligo: where do we stand?
Ortonne JP; Bose SK
Pigment Cell Res; 1993 Mar; 6(2):61-72. PubMed ID: 8321867
[TBL] [Abstract][Full Text] [Related]
31. Vitiligo as an inflammatory skin disorder: a therapeutic perspective.
Taïeb A
Pigment Cell Melanoma Res; 2012 Jan; 25(1):9-13. PubMed ID: 22099450
[TBL] [Abstract][Full Text] [Related]
32. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo.
Tembhre MK; Sharma VK; Sharma A; Chattopadhyay P; Gupta S
Clin Chim Acta; 2013 Sep; 424():27-32. PubMed ID: 23680073
[TBL] [Abstract][Full Text] [Related]
33. The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.
Jin S; Wan S; Xiong R; Li Y; Dong T; Guan C
Inflamm Res; 2024 Jun; ():. PubMed ID: 38839628
[TBL] [Abstract][Full Text] [Related]
34. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
35. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
Steitz J; Brück J; Lenz J; Büchs S; Tüting T
J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
[TBL] [Abstract][Full Text] [Related]
36. Altered regulatory T cell-mediated Natural Killer cells suppression may lead to generalized vitiligo.
Giri PS; Patel SS; Dwivedi M
Hum Immunol; 2024 Jan; 85(1):110737. PubMed ID: 38057201
[TBL] [Abstract][Full Text] [Related]
37. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
38. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
39. Immunopathogenesis of vitiligo.
Sandoval-Cruz M; García-Carrasco M; Sánchez-Porras R; Mendoza-Pinto C; Jiménez-Hernández M; Munguía-Realpozo P; Ruiz-Argüelles A
Autoimmun Rev; 2011 Oct; 10(12):762-5. PubMed ID: 21334464
[TBL] [Abstract][Full Text] [Related]
40. Regulatory T cells and immune tolerance.
Sakaguchi S; Yamaguchi T; Nomura T; Ono M
Cell; 2008 May; 133(5):775-87. PubMed ID: 18510923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
